Halia Therapeutics Presents Two AAIC 2026 Posters on HT-4253 for Alzheimer’s Prevention in APOE4 Carriers
Preclinical data show HT-4253 reduces neuroinflammation and tau pathology; a second details a Phase 2a biomarker trial in pre-symptomatic APOE4 carriers via UAE genomics.
M42’s IROS launches UAE’s first genomics-driven clinical trial to prevent Alzheimer’s disease
Alzheimer’s disease is one of the world’s most pressing health challenges, affecting more than 55 million people globally; a number expected to nearly triple by 2050.
Halia Therapeutics Secures FDA Fast Track for Ofirnoflast
The designation follows encouraging Phase 2 clinical trial results.
Halia Therapeutics Announces Positive Phase 2a Data for Ofirnoflast in Lower-Risk MDS at ASH 2025
New findings demonstrate a 72% HI-E response rate at Week 16 with meaningful hemoglobin improvement.
Halia Therapeutics Expands to Abu Dhabi
Halia Therapeutics Expands to Abu Dhabi
Halia Therapeutics Named as 2025 Top 10 Longevity Breakthrough Award Winner
Halia Therapeutics Named as 2025 Top 10 Longevity Breakthrough Award Winner
Halia Therapeutics Published in Journey of Drug Targeting
Halia Therapeutics Published in Journey of Drug Targeting
Halia Therapeutics Completes First-in-Human Phase 1 Study of HT-4253, a Novel LRRK2 Inhibitor Targeting Neuroinflammation
Completion of SAD/MAD trial marks advancement toward further clinical development of HT-4253 in Alzheimer’s and other neurodegenerative diseases.
Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)
Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)
M42’s IROS and Halia Therapeutics launch clinical study on obesity treatment in the UAE
Trial underscores IROS’s commitment to developing innovative therapies for unmet medical needs
The Future Of Inflammation: The Inflammasome And Beyond
Novel targets for managing inflammation hold the promise of greater efficacy and safety for diseases not widely viewed as inflammatory in nature.
Halia CEO, David Bearss, on Challenges Posed by FDA Project Optimus
Halia Therapeutics’ CEO, David Bearss, recently discussed the FDA’s Project Optimus in The Wall Street Journal.
